Copyright © 2015 - 2022 Lifecarenews.in
LIFE CARE IS REGISTERED MAGAZINE IN RNI, NO.GUJGUJ/2015/71283
Cytokinetics Presents New Data in Patients With
Treatment of Aficamten was Well-Tolerated and Associated with…
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
Cytokinetics
Cytokinetics Presents Positive Results From Cohort 4 of
<!-- Name:DistributionId Value:8781711 -->
<!-- Name:EnableQuoteCarouselOnPnr Value:False -->
<!-- Name:IcbCode Value:4500 -->…
Cytokinetics Receives Complete Response Letter From FDA for
<!-- Name:DistributionId Value:8778875 -->
<!-- Name:EnableQuoteCarouselOnPnr Value:False -->
<!-- Name:IcbCode Value:4500 -->…
Cytokinetics Announces Three Upcoming Presentations at the
<!-- Name:DistributionId Value:8756592 -->
<!-- Name:EnableQuoteCarouselOnPnr Value:False -->
<!-- Name:IcbCode Value:4500 -->…
- Advertisement -
Cytokinetics Announces Outcome of FDA Advisory Committee
PDUFA Target Action Date is February 28, 2023 Cytokinetics to Host Conference Call and Webcast on December 14, 2022 at 8:30 am Eastern Time SOUTH SAN FRANCISCO, Calif., Dec. 13, 2022 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated…
Cytokinetics Announces Availability of Briefing Documents
SOUTH SAN FRANCISCO, Calif., Dec. 09, 2022 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the U.S. Food & Drug Administration (FDA) posted briefing documents for the Cardiovascular and Renal…
Cytokinetics Announces Inducement Grants Under Nasdaq
SOUTH SAN FRANCISCO, Calif., Dec. 02, 2022 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on November 30, 2022 it granted stock options to purchase an aggregate of 146,100 shares of common stock to…